Summary of Key Information:

Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Audited Standalone and Consolidated Financial Results under Regulation 33 of SEBI LODR

Audit Opinion:

Unmodified audit opinion for both standalone and consolidated financial results

Key Financial Highlights [₹ in lakhs]:

Standalone Results:

Revenue from Operations: ₹52,475 (Q1 FY26: ₹43,456) - 20.4% YoY increase

Total Income: ₹53,251 (Q1 FY26: ₹44,025)

Net Profit: ₹5,085 (Q1 FY26: ₹4,496) - 13.1% YoY increase

EPS: ₹5.57 (not annualized)

Expense Breakdown:

  • Cost of materials consumed: ₹43,456 (Q1 FY26: ₹33,381)
  • Purchase of stock-in-trade: ₹1,245 (Q1 FY26: ₹1,121)
  • Changes in inventories: (₹5,766) (Q1 FY26: (₹1,265))
  • Employee benefits expense: ₹2,641 (Q1 FY26: ₹2,329)
  • Finance costs: ₹695 (Q1 FY26: ₹682)
  • Depreciation and amortization: ₹1,521 (Q1 FY26: ₹1,227)
  • Other expenses: ₹11,076 (Q1 FY26: ₹10,134)

Tax Expenses:

  • Provision for taxation - Current: ₹1,600
  • Provision for deferred taxation: ₹100
  • Total tax expenses: ₹1,700

Exceptional Items: ₹209 (write-off of Capital Work-in-Progress)

Consolidated Results:

Revenue from Operations: ₹53,451

Total Income: ₹54,227

Net Profit: ₹5,013

Expense Breakdown:

  • Cost of materials consumed: ₹46,935
  • Purchase of stock-in-trade: ₹2,138
  • Changes in inventories: (₹6,313)
  • Employee benefits expense: ₹3,651
  • Finance costs: ₹922
  • Depreciation and amortization: ₹1,846
  • Other expenses: ₹14,147

Tax Expenses:

  • Provision for taxation - Current: ₹1,768
  • Provision for deferred taxation: ₹105
  • Total tax expenses: ₹1,510

Segment-wise Performance:

Company has only one business segment i.e. pharmaceuticals

Corporate Actions:

Not Specified

Other Significant Information:

  • Average number of equity shares: 91.27 lakh shares (face value ₹10 each)
  • Comprehensive income for standalone: ₹5,085
  • Comprehensive income for consolidated: ₹5,019
  • Subsidiary performance included in consolidation:
  • One subsidiary contributed revenue of ₹8,088.98 lakhs and net profit of ₹597.42 lakhs (audited)
  • Foreign subsidiaries (including step-down) contributed revenue of ₹2,032.48 lakhs and net loss of ₹88.48 lakhs (unaudited management certified)